|   LifeSciVC

Five Macro Risks To Biotech Coming Out of Washington

By Bruce Booth, DPhil, Partner

Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and with more aggressive tax and spending policy in the works, there a number of risks to biotech over the next 1-2 years out of Washington.

Read more.


  |   LifeSciVC

Biotech Funding Tops The Charts Again

By Bruce Booth, DPhil, Partner

Another quarter, another set of all-time highs for biotech funding – and this surfeit of capital continues raises possible concerns about its disciplined deployment.

Read more.


  |   From the Trenches

Reimagining The Workplace Post Pandemic

Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace.  CEO’s that I have spoken with are gravitating towards a hybrid model that requires employees to be on site for specific days but not the entire week.  This is consistent with a recent PWC survey (Figure 1) suggests that only 21% of employers feel that 5 days a week in the office is required to maintain a strong culture.

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   From the Trenches

Scaling Culture With Growth: How to maintain your startup’s “special sauce”

I’ve been thinking a lot about growth, and for good reason: Dyne is in the midst of a significant scale-up.

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   From the Trenches

Ode to Scientists

In the fall of 2019, I wrote a blog called Ode to Patients.  As stresses from many directions have mounted over the past 12 months, it seems that paying heed to another group now makes sense: scientists.

By Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC

Read more.